Dose escalation of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer: A study protocol for a phase 1b TiTE-CRM clinical trial (CRAIN) in UK secondary care centres
Số trang: 10
Loại file: pdf
Dung lượng: 1.58 MB
Lượt xem: 5
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Cervical cancer is the fourth most common cancer in women, with an estimated 342,000 deaths worldwide in 2020. Current standard of care in the UK for locally advanced cervical cancer is concurrent chemoradiotherapy with weekly cisplatin, yet 5-year overall survival rates are only 65% with a distant relapse rate of 50%.
Nội dung trích xuất từ tài liệu:
Dose escalation of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer: A study protocol for a phase 1b TiTE-CRM clinical trial (CRAIN) in UK secondary care centres
Nội dung trích xuất từ tài liệu:
Dose escalation of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer: A study protocol for a phase 1b TiTE-CRM clinical trial (CRAIN) in UK secondary care centres
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Cervical cancer Phase I Concurrent chemoradiotherapy Head and neck squamous cell carcinoma Molecular featureTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 173 0 0 -
6 trang 168 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 144 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 121 0 0 -
12 trang 94 0 0
-
19 trang 75 0 0
-
17 trang 65 0 0
-
9 trang 45 0 0
-
12 trang 39 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 38 0 0